Pear Therapeutics’ $20M Series D Extension

Foley Hoag LLP advised Pear Therapeutics, Inc. on the deal.

Pear Therapeutics, Inc., a pioneer of prescription digital therapeutics (PDTs), announced the extension of its Series D financing, which included a leading national Integrated Delivery Network (IDN) as a new strategic investor. The national IDN invested $20 million, bringing the total Series D investment to $100 million. Pear is using its Series D financing to accelerate reimbursement coverage for its three FDA-authorized products, creating the first market access pathway in the PDT industry.

With offices in Boston, MA, Research Triangle, NC and San Francisco, CA, Pear aims to redefine medicine by discovering, developing and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. The company has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. 

Foley Hoag attorneys David Broadwin (Picture), Jennifer Lichtman, Anna Snook and Alexandra Bender represented Pear in the transaction. 

Involved fees earner: Alexandra Bender – Foley Hoag; David Broadwin – Foley Hoag; Jennifer Lichtman – Foley Hoag; Anna Snook – Foley Hoag;

Law Firms: Foley Hoag;

Clients: Pear Therapeutics Inc;

Martina Bellini

Author: Martina Bellini